12.01.09
Results from a clinical study recently published in the journal Spinal Cord indicate that the use of Cran-Max cranberry concentrate, from Proprietary Nutritionals, Inc. (PNI), in people with spinal cord injury resulted in a significant reduction in both the incidence of urinary tract infection (UTI) and also the number of subjects with a UTI over a 12-month period.
In this randomized, double-blind, cross-over trial, conducted at the Spinal Cord Injury Unit of the Veterans Administration Hospital in Boston, MA, 16 subjects had 21 UTIs while taking the placebo, compared to only 6 subjects who had 7 UTIs while taking the Cran-Max cranberry concentrate.
In the study, patients were randomly assigned to receive either Cran-Max tablets or placebo tablets for 6 months, followed by the alternative preparation for an additional 6 months. Of the 47 male subjects who completed the study, results showed that patients with a high glomerular filtration rate received the most benefit from the cranberry supplement. For further information: www.pnibrands.com
In this randomized, double-blind, cross-over trial, conducted at the Spinal Cord Injury Unit of the Veterans Administration Hospital in Boston, MA, 16 subjects had 21 UTIs while taking the placebo, compared to only 6 subjects who had 7 UTIs while taking the Cran-Max cranberry concentrate.
In the study, patients were randomly assigned to receive either Cran-Max tablets or placebo tablets for 6 months, followed by the alternative preparation for an additional 6 months. Of the 47 male subjects who completed the study, results showed that patients with a high glomerular filtration rate received the most benefit from the cranberry supplement. For further information: www.pnibrands.com